LB Pharma accelerates NOVA-2 trial timeline, expects H1 2027 data
LB Pharmaceuticals moved up its Phase 3 schizophrenia trial topline results to the first half of 2027 due to rapid enrollment, while maintaining strong capitalization through late 2029.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day